Introduction
Obesity is a chronic disease associated with limited quality of life and high morbidity and mortality risks that require long-term medical attention (WHO, 2000, level IV). Care shortages and cost increases are to be expected in health care systems worldwide with increasing frequency of obesity. Efforts to control this problem have already had an effect on the development of treatment guidelines in Scotland, England, France, U.S.A. and other countries.
Guidelines are systematically developed recommendations that are meant to help therapists and patients decide on the appropriate health care in a given case. The recommendations in the guidelines do not include unproven and unnecessary measures in the treatment of the defined diseases.
The goals of the present evidence-based guideline on the prevention and treatment of obesity in Germany are to increase the awareness of obesity as a health problem, to provide therapists and patients guidance and to make disease specific information und recommendations on the prevention and treatment of obesity available to all people in the health care sector, as well as in health politics.
Methodical Procedure in the Development of the Obesity Guideline
In the preparation of the present guideline, a special effort was made to ensure that the requirements of evidence-based medicine were fulfilled. National und international quality criteria for good guidelines, such as those from the Scottish Intercollegiate Guidelines Network (SIGN, 1999) or that jointly compiled by the German Agency for Quality in Medicine (ÄZQ) and the guidelines commission of the German Association of the Scientific Medical Societies (AWMF) (German Agency for Quality in Medicine, 2005), served as a basis for this guideline.
Selection of the Experts
The managing committees of the four participating professional societies appointed recognized and clinically experienced experts and representatives of relevant organizations to the expert committee.
Literature search -The search terms to be used were agreed upon by consensus among the experts, general practitioners and patient representatives. -Comprehensive, systematic, computer-assisted searches in the scientific literature (English und German, clinical studies, meta-analyses) databases of Medline, Cochrane Library, Embase, ERIC and PsycInfo were performed for the period January 2002 to June 2005. Afterwards, a final selection of the literature was made by hand. Moreover, a secondary search in existing guidelines, recommendations, expert opinions and the references found in these texts was also performed. Access to older scientific literature was made possible through an existing database that was established for the first version of the guideline. -The search results were verified for their relevance by specialists (scientists and doctors in the expert committee, nutrition scientists). -Classification of the selected studies according to their study design and their scientific validity into evidence classes I to IV (Table 1) .
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-Discussion of the contents of the guideline drafts and informal consensus in the expert committee. -Presentation of the revised drafts for public discussion in the Internet (websites of the four medical societies). -Consideration of suggestions for modifications received by the expert committee and preparation of the final version. 
Significance and Measurement of Fat Distribution
In addition to the extent of overweight, which is determined by the BMI, the fat distribution pattern also determines metabolic and cardiovascular health risk. The visceral fat mass correlates especially tightly with cardiovascular risk factors and complications (Despres et al., 2001, level IV) . A simple way to evaluate visceral fat is to measure the waist circumference (Lean et al., 1995, level III) .
For women, a waist circumference ≥ 88 cm or for men, ≥ 102 cm is indicative of abdominal obesity (WHO, 2000, level IV; EASO, 2002, level IV). The waist circumference of people with a BMI ≥ 25 kg/m² should always be measured. 
Recommendations for Preventing Obesity

Indication and Goals
The necessity for preventive measures has been established based upon the following findings:
• With increasing duration and degree of obesity, the treatment becomes increasingly more difficult, complex and expensive (Weintraub et al., 1992 , level IIa) • The health sequelae of obesity are not always reversible after weight loss (Pi-Sunyer, 1993, level IV) • In the meantime, the prevalence of obesity in most industrialized nations has become so high that not all affected persons can be offered appropriate treatment (WHO, 2000, level IV)
Weight stabilization is a primary prevention goal at the population level since the average body weight of adults up to the age of 65 years is continually rising (Mensink et al., 2005 , level III). For a BMI between 25 and 29.9, weight stabilization or moderate weight loss is a desirable goal in order to prevent the development of comorbidities and obesity.
Recommendations for Obesity Prevention
There are only a few studies which address the question which preventive measures are suitable and effective. Children und parents from families with elevated obesity risk could be a logical target group for prevention measures. Studies show that effective support programmes for children which lead to long-term weight reduction are especially those that include the parents of the children in the target group for behaviour modification (Epstein et al., 1994, level Ib) . Prevention programmes for adults that aim at a healthy lifestyle and controlling cardiovascular risk factors were only minimally or not at all effective in regards to body weight ( Taylor To achieve a balanced energy intake, preferably foods with lower energy density, that is with high water and dietary fibre contents, but lower sugar and fat contents should be selected. Sporting activity, particularly endurance training, leads to an increase in fatty acid oxidation in the muscles and hence contributes to avoidance of obesity. Prevention of obesity, however, requires additional measures that go beyond a healthy diet. It represents a task involving all of society that must aim at changing adipogenic life conditions. 
Therapeutic Goals
Treatment goals must be realistic and adapted to the individual's conditions. Because obesity can be regarded as a chronic disease with a high tendency for recurrence, an equally important aspect is the assurance of long-term weight control after weight loss. Here the emphasis should be placed on stabilizing the weight or the moderate weight loss of 5 to 10% rather than achieving the ideal or normal weight (SIGN, 1996, level IV). The following treatment goals can be defined individually:
• Reduction of obesity-related morbidity • Reduction of obesity-related mortality
• Increasing the quality of life These therapeutic goals serve the:
• Long-term lowering of body weight • Improvement in health behaviour (energy-balanced diet, regular exercise)
• Strengthening of self-management and stress management capabilities
Preconditions for Treatment
A successful therapy requires an adequately motivated and cooperative patient. Empowerment and personal responsibility are the keys to long-term successful weight management. This calls for comprehensive information on the patient, his/her illness, the complications and treatment. In order to evaluate the individual health risk and to undertake an optimal treatment plan, a careful medical history and specific examinations are necessary before beginning treatment (Hauner, 1997, level IV).
Medical history information • Motivation
• Weight history, previous treatment attempts leptin, ghrelin, adiponectin, etc. * Optional examinations. These serve to diagnose comorbidities and to recognize contraindications for therapeutic measures.
For well-founded suspicion of a syndromic (e.g. Prader-Willi Syndrome) or other monogenetic forms (e.g. MC-4 receptor gene defect) of obesity, molecular genetic diagnostics may be advisable, as long as the tests were not already performed in childhood or adolescence (AGA, 2002, level IV). For this purpose, a specialized centre should be contacted.
Treatment
Basic programme
The foundation for weight management should be a basic programme that includes the elements medical nutrition, exercise and behaviour therapies. A programme for weight management should be made up of two phases. In the first phase, weight reduction is of immediate importance. The purpose of the second phase is weight maintenance and implementing the long-term change in diet to a balanced, varied diet such as is recommended by the German Nutrition Society; this means moderate amounts of fat, high amounts of polysaccharides and dietary fibre and an energy content that facilitates the stabilization of body weight (DGE, 2003, level IV).
Medical nutrition therapy
Medical nutrition therapy comprises different levels or strategies and may begin at any level. The entry level is determined after assessing the individual risk profile and considering the individual circumstances. The patient's complete situation should be considered when planning a dietary change therapy to improve the short and long-term compliance. The patient must be well-informed on the principles of dietary change (SIGN 1996; WHO 2000, level IV). The desired energy deficit can be achieved through the following levels:
Level 1: Reduction of Fat Intake Only
The daily energy deficit should be about 500 kcal. The fat intake is reduced to about 60 grams per day and the consumption of carbohydrates is not limited. An average weight loss of 3.2 to 4.3 kg over a period of six months is possible. The higher the starting weight and previous fat consumption, the greater the loss of weight (Astrup et 
Level 2: Moderately energy-reduced varied diet
Here an energy deficit of 500 to 800 kcal per day is the goal. In addition to a limited fat intake, the consumption of carbohydrates and protein are reduced. Through the increased consumption of plant-derived products, a reduction in energy density while simultaneously maintaining a sensation of satiation is achieved. Thus, an average of 5.1 kg over12 months can be successfully lost (Hauner et al., 2004, level Ib) . This type of diet is largely free of side effects and is also effective over the long-term. It is still the standard therapy for obesity , level Ia). 
Level 4: Formula diets
Through the use of formula diets with a total caloric value of 800 to 1200 kcal/day, it is possible to lose 0.5 to 2 kg/week (NIH, 1998, level IV) over a period of up to 12 weeks. Very low calorie diets (<800 kcal/d) should only be used for people with BMI ≥ 30 kg/m 2 and who should lose weight quickly for medical reasons. A formula diet should always be accompanied by an increase in physical activity. After 12 weeks at the most, a change to a moderately hypocaloric varied diet for weight maintenance should be made. Co-supervision by specialists is advisable due to the elevated side effect risks. A minimum of 2.5 L liquid per day must be drank.
Other types of diets for weight reduction:
With low carbohydrate diets, such as the Atkins diet, rapid weight loss is possible with good compliance in the beginning. However, after 12 months, there is no difference in the course of weight loss between the Atkins diet and a balanced hypocaloric varied diet (Foster et 
Diets with low glycaemic index:
Diets with low glycaemic index (GI) focus on the increased consumption of slowly absorbed carbohydrates that are associated with low postprandial blood sugar and insulin levels. Currently available data do not indicate that a diet with low GI is superior to a diet with high GI (Raben, 2002 Extremely one-sided diets (e.g. total fasting, fasting cures, Schroth cure, Mayr cure, pineapple diet etc.) should not be recommended due to their medical risks and lack of long-term success.
Exercise therapy
Increased physical activity contributes to weight loss and even more strongly to weight maintenance through the higher energy demand. This effect is largely proportional to the energy consumed (Jakicic et al., 2003, level III).
• To measurably reduce weight, an additional energy consumption of 2500 kcal/week is necessary. This corresponds to at least five hours additional physical activity per week It is unclear which exercise frequency, duration and intensity are best for weight maintenance. The training intensity should be based on cardiovascular training and reach about 75% of the maximum heart rate or a calculated heart rate in which the resting heart rate is included (e.g. Karvonen formula) if there are no contraindications. The combination of endurance training with musclebuilding training increases strength and halves the loss of fat-free mass; however, it does not increase the loss of fat (Ballor et al., 1991, level Ia; Jakicic et al., 2001, level IV). The most important elements are: Self-observation of eating, drinking and exercise habits, for example with a diet diary or exercise protocol Gradual introduction of flexible, controlled eating habits (in contrast to rigid behaviour control) Learning stimulus control techniques to decrease eating impulses Use of positive reinforcement (e.g. praise) in order to strengthen new eating habits and prevent relapse Social support Relapse prophylaxis and management
Behaviour therapy
Weight reduction programmes
Commercial weight reduction programmes
Commercial weight reduction programmes usually combine an initial, very low-calorie diet with formula products, increase in physical activity and behaviour modification training with the goal of a long-term change in diet. Most programmes do not have systematic evaluations. For clearly overweight patients (BMI ≥30), the 6-month Optifast programme shows good initial weight loss of about 15 to 25% while taking into account contraindications; however, the majority of the participants regain more than 50% of the weight lost within one to two years (Tsai et 
Other evaluated programmes
The DGE programme "Ich nehme ab" ("I am losing weight"), is a strongly behaviour therapyoriented self-management programme. Through this programme, a moderate reduction of the body weight is to be attained and above all, balanced eating habits established. It was conceived for moderately overweight people without comorbidities. When the programme is applied with adviser support, an average weight loss of 2.3 kg in women and 4.1 kg in men was achieved after one year. At the same time, the participants improved the nutritional composition of their diets (Scholz et al., 2005 , level Ib).
Adjuvant drug therapy
The indication for additional pharmacotherapy for weight loss can be made under the following preconditions (National Task Force on the Prevention and Treatment of Obesity; 1996, level IV):
Patients with BMI ≥ 30, who did not have satisfactory success with the basic programme; this is defined as weight loss ≤ 5% over three to six months or regaining the weight during this period.
Patients with BMI ≥ 27, who additionally have grave risk factors and/or comorbidities and for whom the basic therapy was not successful. The drug therapy should be continued only if a weight loss of at least 2 kg is achieved within the first four weeks.
Medications with weight-reducing potential
Two weight-reducing substances (anorexigenic drugs) are currently authorized for marketing.
Sibutramine:
In randomized, controlled studies in obese patients, the selective serotonin and noradrenaline reuptake inhibitor sibutramine led to a average weight reduction of 2. 
Rimonabant:
Rimonabant is a specific cannabinoid-1 receptor antagonist that was recently approved as a centrally acting weight loss agent. In randomized, controlled trials in overweight subjects (BMI ≥ 27 kg/m 2 ) with and without comorbidities (dyslipidaemia, type 2 diabetes), 20 mg rimonabant reduced body weight by an average of 3.9 to 6.7 kg over a 12-month treatment period (van Gaal et al. Records on the clinical use of sibutramine, orlistat and rimonabant are available for only a limited duration of two or four years; thus, longer use cannot be recommended. For all substances, prospective studies with cardiovascular outcomes are not available. The benefit of combinations of these active substances has not been adequately studied.
Substances such as diuretics, growth hormones, amphetamines and thyroxine cannot be recommended for the treatment of obesity due to their unproven effects or dangerous side effects. Metformin and acarbose show weak weight-reducing effects of 0. . Strict standards must be applied to the surgical risk associated with this elective surgery; in no case may the risk exceed the risks known from similar elective surgeries. The patients must be sufficiently motivated and must completely comprehend the surgical procedure, its risks and long-term consequences (informed consent). Normally, several consultations are required. A patient's lack of compliance can lead to life-threatening complications after obesity surgical interventions (Sauerland et al., 2005 , level IV).
Before making the diagnosis, the patient should have attempted conservative treatment according to defined quality criteria for at least 6 to 12 months. A psychological or psychosomatic therapy preceding surgical treatment does not appear to be fundamentally required; for patients with suspected depression, psychosis, addiction or eating disorder such as binge eating, a psychiatrist or psychotherapist must be consulted. If psychotherapy seems to be promising for a patient with an eating disorder, this should be first attempted before surgical therapy. Eating disorders, in particular binge eating syndrome, are not fundamentally contraindications for obesity surgical measures (Busetto et al., 2005 , level III).
The decision which surgical procedure, restriction or a combination of restriction and malabsorption, is appropriate for a given case, is dependent on BMI, the individual risk, the comorbidities and the patient's wishes (Sauerland et al., 2005 , level IV). Decision criteria are not evaluated. For patients with good compliance and BMI < 50, restrictive procedures (adjustable stomach band or possibly gastric banding) could be appropriate (Husemann, 2003, level IV) . For patients with BMI ≥ 50 kg/m², usually a combination procedure such as stomach bypass, duodenal switch, or possibly a biliopancreatic diversion is used since greater and more stable weight loss can be achieved (Sjöström et al., 2004, level IIa) . Whenever possible, laparoscopy is preferred (Sauerland et al., 2005 , level IV).
Perioperative complications occur in 5 to 15% of the patients and mostly concern wound healing impairment (3 to 12%) or cardiovascular problems such as thrombosis (1 to 9%) or pulmonary embolism (0.2 to 1.5%). Perioperative mortality is about 1% (Husemann, 2003, level IV) . In recent US American analyses on large collectives, a hospital mortality of 0.1 to 0.2% (Santry et al., 2005 , level III) and however, also a 30-day mortality of 2.0% were reported, in which the rate for men was double that of women (Flum et al., 2005 , level III). Due to possible late complications, interdisciplinary long-term aftercare of the patients must be ensured. Most complications are related to local anatomical problems in the operated area and to chronic malnourishment as a result of malabsorption. Liposuction is a method from plastic surgery that can be employed for the removal of local fat deposits, but which is not suitable for the treatment of obesity. A benefit of this technique for longterm weight loss has not been demonstrated; the risks of this intervention are poorly documented and are not insignificant. Plastic surgical procedures may be necessary after successful weight reduction to remove excess skin and also to correct the risk of chronic skin infections.
Long-term weight stabilization
Long-term results of weight management programmes are critically dependent upon the long-term support concept. The following factors must be considered:
Because energy consumption during a weight reduction diet declines, a return to the previous lifestyle leads to weight gain (Leibel et al., 1995, level IIa The changes in the parameters for morbidity usually depend upon the starting values; greater changes are expected with higher starting values.
Disadvantages of weight reduction
After weight reduction, there is an elevated risk for gall stone diseases. The faster and more pronounced the weight loss, the more frequently gall stones develop (Everhart, 1993, level IV) . Drastic weight reduction is often associated with loss in bone density. In Caucasian women who started weight reduction after the age of 50, an elevated incidence of hip fractures was observed (Langlois et al., 1996 , level III). Health drawbacks due to weight cycling could not be confirmed (National Task Force on the Prevention and Treatment of Obesity, 1994, level Ia). There is also no evidence supporting the assumption that diets or weight reduction programmes promote the development of eating disorders (National Task Force on the Prevention and Treatment of Obesity, 2000, level Ia).
Medical Care Aspects
The family doctor plays a central role in the long-term care of overweight or obese patients. Obese patients with particular comorbidities or treatment problems should receive additional care in specialized treatment facilities (e.g. medical practices or centres specializing in nutritional medicine or diabetes or outpatient and stationary rehabilitation facilities).
For obese persons with grave concomitant diseases or serious psychosocial problems, initial care by obesity specialists in private practice or in an outpatient obesity centre may be advisable or necessary (SIGN, 1996, level IV; NIH, 1998, level IV). Such institutions should fulfil defined quality criteria for outpatient obesity programmes and be subjected to continuous quality control (Hauner et al., 2000, level IV) . Electronic documentation systems such as, for example, the apv programme can support quality management. Quality criteria Spatial requirements
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